- Home
- INDP vs GRI Comparison
INDP vs GRI Comparison
Compare INDP & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDP
- GRI
- Stock Information
- Founded
- INDP 2000
- GRI 2018
- Country
- INDP United States
- GRI United States
- Employees
- INDP N/A
- GRI N/A
- Industry
- INDP Biotechnology: Pharmaceutical Preparations
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- INDP Health Care
- GRI Health Care
- Exchange
- INDP Nasdaq
- GRI Nasdaq
- Market Cap
- INDP 4.0M
- GRI 4.3M
- IPO Year
- INDP N/A
- GRI N/A
- Fundamental
- Price
- INDP $2.60
- GRI $1.82
- Analyst Decision
- INDP Strong Buy
- GRI Strong Buy
- Analyst Count
- INDP 1
- GRI 2
- Target Price
- INDP $140.00
- GRI $22.50
- AVG Volume (30 Days)
- INDP 67.5K
- GRI 170.6K
- Earning Date
- INDP 11-07-2025
- GRI 11-14-2025
- Dividend Yield
- INDP N/A
- GRI N/A
- EPS Growth
- INDP N/A
- GRI N/A
- EPS
- INDP N/A
- GRI N/A
- Revenue
- INDP N/A
- GRI N/A
- Revenue This Year
- INDP N/A
- GRI N/A
- Revenue Next Year
- INDP N/A
- GRI N/A
- P/E Ratio
- INDP N/A
- GRI N/A
- Revenue Growth
- INDP N/A
- GRI N/A
- 52 Week Low
- INDP $2.22
- GRI $1.10
- 52 Week High
- INDP $47.60
- GRI $16.95
- Technical
- Relative Strength Index (RSI)
- INDP 40.51
- GRI 50.96
- Support Level
- INDP $2.45
- GRI $1.56
- Resistance Level
- INDP $3.76
- GRI $1.79
- Average True Range (ATR)
- INDP 0.28
- GRI 0.15
- MACD
- INDP -0.06
- GRI -0.01
- Stochastic Oscillator
- INDP 26.80
- GRI 46.03
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.